Images List Premium Download Classic

Therapeutical

Therapeutical-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
The Trustees Of The University Of Pennsylvania
September 14, 2017 - N°20170261508

A method for diagnosing or treating a mammalian subject having, or at risk of developing cancer, comprising: generating a circulating anti-cancer cd4+ th1 response from antigen presenting cells or their precursors and cd4+ t-cells from a sample of said subject's blood which causes secretion of interferon-gamma (“ifn-γ”); and detecting said anti-cancer cd4+ th1 response ...
Reagents and methods for engaging unique clonotypic lymphocyte receptors
The Johns Hopkins University
September 14, 2017 - N°20170261497

Platforms comprising at least one lymphocyte affecting molecule and at least one molecular complex that, when bound to an antigen, engages a unique clonotypic lymphocyte receptor can be used to induce and expand therapeutically useful numbers of specific lymphocyte populations. Antigen presenting platforms comprising a t cell affecting molecule and an antigen presenting complex can induce and expand antigen-specific t ...
Novel selenazolidine and thiazolidine compounds for treating cancer and other diseases
The Penn State Research Foundation
September 14, 2017 - N°20170260151

The present invention includes compounds useful in preventing or treating cancer in a subject in need thereof. The present invention also includes methods of preventing or treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention.
Therapeutical Patent Pack
Download 734+ patent application PDFs
Therapeutical Patent Applications
Download 734+ Therapeutical-related PDFs
For professional research & prior art discovery
inventor
  • 734+ full patent PDF documents of Therapeutical-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
Syndevrx, Inc.
September 14, 2017 - N°20170258925

One aspect of the invention provides polymer conjugated metap2 inhibitors. While not being bound by any particular theory, it is believed that coupling the metap2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated metap2 inhibitors are useful in ...
Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
Merrimack Pharmaceuticals, Inc.
September 14, 2017 - N°20170258903

Methods for treating cancer patients (e. G., cancer patients resistant or intolerant to pertuzumab and ado-trastuzumab emtansine) with her2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of a doxorubicin-loaded immunoliposome with a targeting moiety that is an anti-her2 antibody that is not an inhibitor of her2 signaling and an ...
Method of treating seasonal affective disorder
Merrimack Pharmaceuticals, Inc.
September 14, 2017 - N°20170258879

Methods are provided for treating or preventing seasonal affective disorder caused by the onset of a specific season in a subject. The method include administering a therapeutically effective amount of a neurotoxin to a facial muscle to cause paralysis of the facial muscle, thereby affecting the ability of the subject to frown and thus treating or preventing the seasonal affective ...
Therapeutical Patent Pack
Download 734+ patent application PDFs
Therapeutical Patent Applications
Download 734+ Therapeutical-related PDFs
For professional research & prior art discovery
inventor
  • 734+ full patent PDF documents of Therapeutical-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods of treating graft versus host disease (gvhd) or epidermolysis bullosa (eb)
Agency For Science, Technology And Research
September 14, 2017 - N°20170258845

We describe the use of exosome such as mesenchymal stem cell exosomes in a method of promoting, restoring or enhancing homeostasis in an individual suffering from graft versus host disease (gvhd) or epidermolysis bullosa (eb). The homeostasis may comprise immune homeostasis such as maintenance of an immune response. The method may comprise administering a therapeutically effective amount of exosome to ...
Engineering and delivery of therapeutic compositions of freshly isolated cells
Maxcyte, Inc.
September 14, 2017 - N°20170258837

The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as pbmc, pbl, t (cd3+ and/or cd8+) and natural killer (nk) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates ...
Method for treating cancer
Maxcyte, Inc.
September 14, 2017 - N°20170258827

A method for treating a cancer by administering a therapeutically active composition for the treatment in a patient or human thereof, is disclosed. The method according to the present invention, comprises a step of administering to the human a pharmaceutical composition comprising a therapeutic amount of sodium thiosulfate (na2s2o3) along with at least one of a pharmaceutical carrier ...
Alkyl linked quinolinyl modulators of rorγt
Maxcyte, Inc.
September 14, 2017 - N°20170258782

The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
Compositions and methods of treating cardiac fibrosis with ifetroban
Vanderbilt University
September 14, 2017 - N°20170258771

The present invention is directed to methods of treating, preventing, and/or ameliorating fibrosis syndrome, and in particular cardiac fibrosis, by administration of a therapeutically effective amount of ifetroban, or a pharmaceutically acceptable salt thereof.
Rapid disperse dosage form
Aprecia Pharmaceuticals Company
September 14, 2017 - N°20170258763

A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug.
Bacterially derived intact minicells that encompass plasmid free dna and methods of using the same
Engeneic Molecular Delivery Pty Ltd.
September 14, 2017 - N°20170258734

Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
Therapeutical Patent Pack
Download 734+ patent application PDFs
Therapeutical Patent Applications
Download 734+ Therapeutical-related PDFs
For professional research & prior art discovery
inventor
  • 734+ full patent PDF documents of Therapeutical-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Evaluation of the potential risk of drug induced mood disturbance and suicide: use of a ...
Alcediag
September 07, 2017 - N°20170253926

The present invention relates to in vitro methods for the determination of the potential toxicity of test compounds. The invention also comprises in vitro methods for the selection of therapeutical compounds useful for the treatment of pathology related to an alteration of the mechanism of the mrna editing of adar dependent a to i mrna editing of the serotonin 2c ...
Compositions and methods of selectively inhibiting irp1 and treating inflammation
Technion Research & Development Foundation Limited
September 07, 2017 - N°20170253881

Compositions and methods of treating an inflammatory disease in a subject are provided. Accordingly there is provided a method comprising administering to the subject a therapeutically effective amount of an agent which selectively inhibits activity and/or expression of iron regulatory protein (irp) 1 and not irp2, thereby treating the inflammatory disease in the subject. Also provided is a pharmaceutical composition ...
Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an ...
Regeneron Pharmaceuticals, Inc.
September 07, 2017 - N°20170253666

The present invention provides methods for treating patients suffering from hypercholesterolemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that ...
Anti-gd2 antibodies
Memorial Sloan Kettering Cancer Center
September 07, 2017 - N°20170253660

In this application are described chimeric, humanized, affinity matured, stability enhanced, and bispecific anti-gd2 antibodies and fragments thereof. Also provided are methods of using individual antibodies or compositions thereof for the detection, prevention, and/or therapeutical treatment of gd2-related diseases, in particular, neuroblastoma.
Method for treating parkinson disease, neurodegenerative disorders, and autoimmune diseases
Memorial Sloan Kettering Cancer Center
September 07, 2017 - N°20170252369

The embodiments herein relate to a therapeutic method for the treatment of parkinson disease, other neurodegerative disorders, and autoimmune diseases. The method includes providing sodium thiosulfate through any method of administration (orally, intravenously, through inhalation, intravesically, vaginally, rectal route, sublingually, ophthalmically, or topically) and is given with one or more pharmaceutically acceptable carriers or excipients. The sodium thiosulfate safely and ...
Steroidal compositions
Lipocine Inc.
September 07, 2017 - N°20170252357

Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to ...
Combination of ceritinib with an egfr inhibitor
Novartis Ag
September 07, 2017 - N°20170252335

The present disclosure relates to a pharmaceutical composition comprising two tyrosine kinase inhibitors (tkis), namely ceritinib and an egfr inhibitor. The present combination can be administered independently or separately, in a quantity which is jointly therapeutically effective for the treatment of a tki mediated disease, such as cancer. The disclosure also provides the use of such a combination for the ...
Compositions and methods of inhibiting metallo-beta-lactamases
Case Western Reserve University
September 07, 2017 - N°20170252326

A method of treating a bacterial infection in a subject in need thereof includes administering to the subject therapeutically effective amounts of at least one β-lactam antibiotic and at least one bisthiazolidine metallo-β-lactamase inhibitor.
Loading